12 Amendments of Karin KADENBACH related to 2011/0401(COD)
Amendment 72 #
Proposal for a regulation
Article 4 – paragraph 1
Article 4 – paragraph 1
Horizon 2020 shall play a central role in the delivery of the Europe 2020 strategy for smart, sustainable and inclusive growth by providing a common strategic framework for the Union's research and innovation funding, thus acting as a vehicle for leveraging private investment, creating new job opportunities, better health and health outcomes and ensuring Europe's long-term sustainable growth and competitiveness.
Amendment 101 #
Proposal for a regulation
Article 12 – paragraph 1
Article 12 – paragraph 1
1. For the implementation of Horizon 2020, account shall be taken of advice and inputs provided by: advisory groups of independent, high level experts set up by the Commission; dialogue structures created under international science and technology agreements; forward looking activities; targeted public consultations (e.g. of patient organizations where health research is concerned); and transparent and interactive processes that ensure responsible research and innovation is supported.
Amendment 150 #
Proposal for a regulation
Article 25 – paragraph 1
Article 25 – paragraph 1
1. The Commission shall annually monitor the implementation of Horizon 2020, its specific programme and the activities of the European Institute of Innovation and Technology, with the input of relevant outside stakeholders, e.g. patient organizations. This shall include information on cross-cutting topics such as sustainability and climate change, including information on the amount of climate related expenditure.
Amendment 232 #
Proposal for a regulation
Annex I – part III – point 1.1 – paragraph 2
Annex I – part III – point 1.1 – paragraph 2
The cost of Union health and social care systems is rising with care and prevention measures in all ages increasingly expensive, the number of Europeans aged over 65 expected to nearly double from 85 million in 2008 to 151 million by 2060, and those over 80 to rise from 22 to 61 million in the same period. Reducing or containing these costs such that they do not become unsustainable depends in part on ensuring the lifelong health and wellbeing of all and therefore on the effective prevention, as well as access to appropriate and specialised treatment and management of disease and disability, including in expert centres.
Amendment 241 #
Proposal for a regulation
Annex I – part III – point 1.1 – paragraph 3
Annex I – part III – point 1.1 – paragraph 3
Chronic conditions such as cardiovascular disease (CVD), pulmonary disease, cancer, diabetes, neurological and mental health disorders, overweight and obesity and various functional limitations are major causes of disability, ill-health and premature death, and present considerable social and economic costs.
Amendment 257 #
Proposal for a regulation
Annex I – part III – point 1.1 – paragraph 6
Annex I – part III – point 1.1 – paragraph 6
Meanwhile, drug and vaccine development processes are becoming more expensive and less effective. Persistent health inequalities must be addressed, and access to effective and competent health systems – i.e. access to health expertise, early diagnose, appropriate treatment and quality care - must be ensured for all Europeans.
Amendment 267 #
Proposal for a regulation
Annex I – part III – point 1.2 – paragraph 3
Annex I – part III – point 1.2 – paragraph 3
Similarly, the complexity of the challenge and the interdependency of its components demand a European level response. Many approaches, tools and technologies have applicability across many of the research and innovation areas of this challenge and are best supported at Union level. These include the development of long term cohorts and the conduct of clinical trials, the clinical use of ‘"-omics’" or the development of ICT and their applications in healthcare practice, notably e-health. The requirements of specific populations are also best addressed in an integrated manner, for example in the development of stratified and/or personalised medicine, care provided in multi-disciplinary expert centres, in the treatment of rare diseases, and in providing assisted and independent living solutions.
Amendment 269 #
Proposal for a regulation
Annex I – part III – point 1.2 – paragraph 4
Annex I – part III – point 1.2 – paragraph 4
To maximise the impact of Union level actions, support will be provided to the full spectrum of research and innovation activities. From basic research through translation of knowledge to large trials and demonstration actions, mobilising private investment; to public and pre- commercial procurement for new products, services, scalable solutions, which are when necessary, interoperable and supported by defined standards and/or common guidelines. This co-ordinated, European effort will contribute to the ongoing development of the ERA. It will also interface, as and when appropriate, with activities developed in the context of the Health for Growth Programme and, the European Innovation Partnership on Active and Health Ageing and future actions in relation to chronic conditions.
Amendment 270 #
Proposal for a regulation
Annex I – part III – point 1.3 – paragraph 1
Annex I – part III – point 1.3 – paragraph 1
Effective health promotion, supported by a robust evidence base, prevents disease, improves wellbeing and is cost effective. Health promotion and disease prevention also depend on an understanding of the determinants of health, on effective preventive tools, such as vaccines, on effective health and disease surveillance and preparedness, and on effective screening programmes and on access to timely, high quality, appropriate and specialized treatment.
Amendment 277 #
Proposal for a regulation
Annex I – part III – point 1.3 – paragraph 2
Annex I – part III – point 1.3 – paragraph 2
Successful efforts to prevent, manage, treat and cure disease, disability and reduced functionality are underpinned by the fundamental understanding of their determinants and causes, processes and impacts, as well as factors underlying good health and wellbeing. Effective sharing of data and the linkage of these data with large scale cohort studies is also essential, as is the translation of research findings into the clinic, in particular through the conduct of clinical trials (e.g. carried out in multi-disciplinary disease-specific expert centres).
Amendment 283 #
Proposal for a regulation
Annex I – part III – point 1.3 – paragraph 3
Annex I – part III – point 1.3 – paragraph 3
An increasing disease and disability burden in the context of an aging population places further demands on health and care sectors. If effective health and care is to be maintained for all ageindividuals, irrespective of their age or gender and economic means, efforts are required to improve decision making in prevention and treatment provision, to identify and support the dissemination of best practice in the health and care sectors, and to support integrated care (provided in expert centres where appropriate), and the wide uptake of technological, organisational and social innovations empowering in particular older persons as well as disabled persons and patients to remain active and independent. Doing so will contribute to increasing, and lengthening the duration of their physical, social, and mental well-being. and quality of life.
Amendment 294 #
Proposal for a regulation
Annex I – part III – point 1.3 – paragraph 5
Annex I – part III – point 1.3 – paragraph 5
Specific activities shall include: understanding the determinants of health (including environmental and climate related factors), improving health promotion and disease prevention; understanding disease and improving diagnosis; developing effectiveand improving access to effective and specific screening programmes and improving the assessment of disease susceptibility; develop cures for neglected diseases; improving surveillance and preparedness; developing better preventive vaccines; using in-silico medicine for improving disease management and prediction; treating disease; transferring knowledge to clinical practice and scalable innovation actions; better use of health data; active ageing, independent and assisted living; individual empowerment for self-management of health; promotion of integrated care including care and treatment provided in multidisciplinary disease-specific expert centres ; improving scientific tools and methods to support policy making and regulatory needs; and optimising the efficiency and effectiveness of healthcare systems and reducing inequalities by evidence based decision making and dissemination of best practice (e.g. on the most effective care delivery, valued by patients) , and innovative technologies and approaches.